# Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

> **NCT07382713** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jinhua Zhou** · enrollment: 43 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Fluzoparib

## Key facts

- **NCT ID:** NCT07382713
- **Lead sponsor:** Jinhua Zhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382713, "Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07382713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*